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Abstract  
Arthrogenic pain is a common problem in equids. Frequently used treatments such as 
systemic NSAIDs or intra-articular steroids can lead to severe side effects if used 
repeatedly. Gold has been used since ancient times to treat a variety of conditions and has 
anti-inflammatory and immunomodulating properties. Results from clinical and in vitro 
studies suggest that local gold might provide a safe and effective alternative to alleviate 
articular pain. In particular, gold micro-implants have been proposed to this end, but it is 
unknown if and how healthy joints react to this treatment.  
The aim of this study was to evaluate the safety of gold micro-implants (Berlock®-Micro-
Implants) mixed with hyaluronic acid and injected into the middle carpal joint of 9 healthy 
horses. Each horse was treated in one carpus and sham-treated on the contralateral.  
Lameness, carpal temperature increase, swelling and reactions to joint palpation were 
observed in both treated and sham-treated carpi in the first week following needle arthroscopy 
and treatment. Significant differences between treated and sham-treated carpi were found only 
for mechanical nociceptive thresholds 4 days after treatment. Higher thresholds were found in 
treated joints compared to sham-treated joints.  None of the outcome measures selected in the 
present study indicated systemic or local adverse effects specifically attributed to gold micro-
implants.  
In the absence of systemic and local adverse reactions to gold micro-implants, the results of 
the present study support future clinical trials to test the pain-relieving efficacy of this 
treatment modality in sub-acute or chronic articular inflammatory processes in equine 
patients. 
 
Key Words: gold; horse; intra-articular; micro-implants; Berlock®   
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1. Introduction 
Osteoarthritis (OA) is a common cause of pain and lameness in equids, it is a 
career limiting disease in both sport and leisure horses. The most frequently used 
treatments are oral or intravenous NSAIDS, or intra-articular steroids [1]. Despite their 
proven efficacy severe side effects might be encountered in case of prolonged therapy. 
This limits their applicability and safe alternatives are needed.  
 
Gold has been used since ancient times for its anti-inflammatory and 
immunomodulating properties [2, 3]. Originally conceived as a way to continuously 
stimulate acupuncture points [4], periarticular gold implants, several millimeters in 
diameter, have been used to obtain long-lasting pain control in OA [5-7]. Experimental 
studies showed that gold ions, the active component in aurotherapy, are released from 
implanted gold by dissolucytosis, an extracellular process performed by macrophages. 
This can only occur when the implant is at least 20 µm in size as smaller particles are 
phagocytized and no gold ions are released [8, 9]. Gold micro-implants (20-40 µm) tested 
in vitro and in vivo in experimental animals  have been patented for direct application in 
inflamed tissues, including joints (Berlock®-Micro-Implants (BMI), Goldtreat ApS) [10]. 
For administration, BMI are mixed with hyaluronic acid (HA) in order to guarantee an 
adequate distribution. The local release of gold ions, with their anti-inflammatory activity, 
is enhanced in inflamed tissue, thus providing the rationale for intra-articular use of gold 
implants in equine OA. To date, no safety data for intra-articular BMI application can be 
found in the literature. Prior to initiating clinical trials focusing on the pain-relieving 
efficacy of BMI  in equine OA, the occurrence of major adverse reactions needs to be 
ruled out. Only then will it be acceptable to recruit and treat client-owned horses with 
BMI.  
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The aim of this study was to evaluate the safety of intra-articular BMI mixed with 
HA in healthy horses.  In each horse, one middle-carpal joint was treated with BMI mixed 
with HA while the other was treated with HA alone as a control.  In order to detect any 
potential systemic or local adverse effects arising from the BMI treatment, several 
outcome measures were evaluated over a period of 3 months.  
 
2. Materials and Methods 
2.1 Study design and ethical statement 
The study, designed as a blinded, randomized, controlled, prospective experimental 
trial, was approved by the Cantonal Authority for Animal Experiments, Canton Bern and 
Vaud, Switzerland (BE105/12). All procedures were carried out under strict rescue 
analgesia regimen. If any horse showed signs of pain, reaching a score  >9/36 on the 
composite pain scale (Appendix 1), or a lameness degree greater than 2/5 at any time 
during the study, further clinical evaluations were performed and analgesic treatment 
administered according to specific clinical signs. Flunixin (1 mg/kg IV) was administered 
in case of lameness (>2/5) and/or swelling (score ≥ 2) (Appendix 2). In case of persistent 
(>3 days) moderate or acute severe joint pain or swelling, joint flushing and intra-articular 
administration of morphine 0.1 mg/kg under general anesthesia was planned. 
 
2.2 Animals 
Nine healthy horses (8 females, 1 castrated male) belonging to the Swiss Institute 
of Equine Medicine (ISME) without any signs of carpal pathology were included in the 
study. Horses had a median age of 10.2 years (range 10-18) and a median bodyweight of 
580 kg (range 498-645 kg). Breeds included 3 Franche Montagnes horses, 3 Swiss 
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Warmbloods, 2 Trotters and 1 Hannoverian (Table 1). Eight horses were stabled together 
in an open barn with access to an outdoor pen, they were fed 3 times a day with hay and 
the resting area was bedded with straw, the access to water was unlimited. The remaining 
horse was stabled individually in a box bedded with shavings and was exercised daily on a 
walker or through paddock-turnout. This horse was fed haylage three times a day, with ad 
libitum access to water. 
 
2.3  Inclusion criteria 
Prior to inclusion in the study all horses underwent full clinical and hematological 
examinations. Radiological evaluation of the carpal joints was performed, with three 
radiographs taken of both carpi (Dorsomedial-palmarolateral oblique, dorsolateral-
palmaromedial oblique and flexed latero-medial). Only horses that had normal bloodwork, 
showed no radiological abnormalities, no lameness and no signs of pain were included in 
the study.  
  
2.4 Outcome measures 
Outcome measures, as detailed below, were recorded by 2 investigators blinded to 
the treatment (NM and SW), before the treatment and up to 3 months thereafter according 
to the schedule shown in Table 2.  
 
2.4.1 Pain score 
A modification of the multifactorial numerical rating composite pain scale 
published by Bussières et al. (2008) [11] was used to evaluate pain and guide 
administration of rescue analgesia (Appendix 1). 
 
2.4.2 Lameness and symmetry index  
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Subjective lameness examination was performed with the horses trotting in a 
straight line on a loose rope on a hard, even surface. A score from 0 to 5 (where 0: 
clinically sound and 5: non-weight bearing lameness, details in Appendix 2) was 
attributed to each horse before and after 1 minute of carpal flexion. Objective lameness 
evaluation was performed  using data collected from a poll-mounted three-dimensional 
accelerometer processed according to published algorithms [12, 13] using MatLab (The 
MathWorks, Inc.) by custom-made software (Equigait) [14]. The generated symmetry 
index was interpreted using previously established values for non-lame horses [15]. 
Symmetry indexes of below 0.82 and greater than 1.18 indicated right and left forelimb 
lameness’ respectively. 
 
2.4.3 Carpal variables 
Joint swelling was scored using a 0-3 numerical rating scale (Appendix 2).  
Carpal circumference was measured using a standard measuring band at the distal 
aspect of the accessory carpal bone.  
Temperature of the carpus was quantified from  frontal thermographic images of 
both carpi, collected with an infrared camera (InfraVet OptiRes D, VarioCAM, Infra Tech 
GmbH, Dresden, Germany)  and analyzed with custom software (Exam Professional 5.8, 
InfraMedic GmbH, Germany). Horses were restrained in stocks for 30 minutes before the 
images were taken to avoid artifacts from ambient temperature changes and locomotion. 
The camera was positioned 1 m from the carpi for all readings. Temperature differences 
between the two carpi were calculated for each session. Differences of ≥1.25°C between 
the carpi were considered clinically relevant [16]. 
Reactions to palpation of the middle carpal and carpometacarpal joints were scored 
using a 0-3 numerical rating scale (Appendix 2).  
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Mechanical nociceptive thresholds (MNT) were determined using a calibrated 
hand-held algometer (FDN 200, Wagner Instruments, Greenwich CT, USA) with a rubber 
tip  1 cm² in diameter and a maximal capacity of 20 Kg. Pressure was applied 
perpendicular to the skin surface on 7 predetermined anatomical landmarks along the front 
limb and was immediately released when the horse showed first signs of discomfort (e.g. 
lifting of the limb, twitching of the skin) or the pressure applied had reached 12 Kg/cm2 
(cut-off value). A rate of pressure increase of approximately 2 Kg/cm2/s was used for each 
measurement. Selection of landmarks was based on a previous report [17] and modified to 
assure evaluation of the area of interest (Appendix 2). Landmarks were evaluated in 
random order twice; a mean threshold value was calculated for each landmark and used 
for analysis.   
Passive joint range of motion was measured as described by Liljebrink and Bergh 
(2010) [18] using a calibrated goniometer which could be fixed in place and read 
afterwards using a standard set-square with integrated protractor. 
 
Ultrasonographic evaluations of the synovial lining were performed by one of two 
examiners blinded to the treatment (SW, NM) using a portable ultrasound (M-Turbo; 
SonoSiteTM, Bothell, WA, USA) with a C11x/8-5 MHz linear transducer. Images of the 
joint-space between the radiocarpal bone and third carpal bone (dorsomedial) and the 
joint-space between the intermediate carpal bone and the third carpal bone (dorsolateral) 
were obtained in both B-Mode and Doppler-Mode. Each middle carpal joint was scored in 
accordance with the human sonographic definition of synovitis or synovial hypertrophy as 
per OMERACT 7 [19] on a 0-3 numerical rating scale. Scores were defined as 0: normal 
synovial lining; 1: mild hypoechoic synovial thickening; 2: moderate hypoechoic synovial 
thickening; 3: marked hypoechoic synovial thickening.  
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2.4.4 Needle arthroscopy 
Needle arthroscopy was performed to allow thorough evaluation of the intra-articular 
architecture of both middle-carpal joints immediately prior to treatment administration 
and 3 months thereafter. Horses were premedicated with 0.03 mg/kg acepromazine  IM 
(Prequilan, Arovet AG, Switzerland) and sedated with a bolus of 0.05 mg/kg methadone 
(L-Polamivet, MSD Animal Health GmbH, Switzerland) and 0.05 mg/kg romifidine 
(Sedivet, Boehringer Ingelheim, Germany) IV. Sedation was maintained by IV continuous 
rate infusion of 0.05 mg/kg/h methadone and 0.05 mg/kg/h romifidine in Ringer Lactate 
(Laboratorium Dr. G. Bichsel AG, Switzerland) titrated to effect. Following routine 
preparation for surgery, lidocaine (Lidocaine 2% Streuli, G. Streuli & Co. AG, 
Switzerland) was injected subcutaneously (2 ml) and intra-articularly (20 ml) to distend 
the joint during endoscopy. Subsequently, a semi-rigid, 1.2 mm (outer diameter), 10° 
optic needle endoscope with a working length of 100 mm (BioVision, Golden, CO) was 
used to evaluate the middle carpal joint and standard images were obtained. In case of 
abnormal findings, a thorough description of the visualized altered structures was 
provided. All examinations were carried out by the same experienced orthopedic surgeon 
(SW). Time to perform the procedure was recorded. Flunixine meglumine (1 mg/kg IV) 
(Fluniximin, Dr. E. Graeub AG, Switzerland) was administered postoperatively. The 
horses were confined to a box stall for 2 days before returning to their normal stabling and 
routine.  
 
2.4.5 Blood and synovial fluid analysis 
Venous blood was collected for routine hematology, biochemical evaluation and to 
determine serum amyloid A (SAA) concentration. 
Synovial fluid samples were collected into plain tubes. An aliquot was diluted 1:20 
in isotonic NaCl 0.9% and the number of nucleated cells immediately determined by a 
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blinded investigator using a Neubauer counting chamber on a Leica microscope with 40 x 
magnification. The remaining synovial fluid was centrifuged at 1200 g to pellet cells and 
cell-free supernatant frozen in 1 ml aliquots and stored at -80°C until further analysis. 
Levels of IL-1β, TNF-α, Aggrecan Chondroitin Sulfate and Substance P in the 
synovial fluid were determined according to the manufacturers protocol using the 
following commercially available ELISA kits: GSI Equine IL-1β ELISA Kit- Synovial 
Fluid (Genorise Scientific, Inc, USA), GSI Equine TNF alpha ELISA Kit- Synovial Fluid 
(Genorise Scientific, Inc, USA), Aggrecan Chondroitin Sulfate 846 Epitope (CS846 
ELISA, IBEX Pharmaceuticals Inc., Canada), Substance P EIA Kit (Cayman Chemical 
Company, Ann Arbor, MI).  
 
2.5 Treatment 
Each horse underwent bilateral carpal treatment on day 0: immediately following 
needle arthroscopy and synovial fluid sampling, one joint (randomly determined) was 
injected with 1 vial of BMI mixed with 2 mL HA (treated) while the other was injected 
with 2 mL HA alone (sham-treated) (Table 1).  
One vial of BMI consisted of 10 mg of gold (approximately 36.000 particles, 20-40 
µm in size). Prior to administration, hyaluronic acid (20 mg, Ostenil, Trb Chemedica S.A., 
Switzerland) was aseptically injected into the vial and shaken until the gold particles were 
adequately suspended. All horses were treated within 2 consecutive weeks. 
 
2.6 Statistics 
Analysis was performed with the statistical computing package R. Descriptive 
statistics were calculated for all outcome measures and medians and ranges reported. The 
data were analyzed at individual time points using a linear regression model and over time 
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using a linear regression model with horse specific random effects on the treatment 
difference. All models were stratified by horse to acknowledge that each horse was both 
treated and sham-treated and a two-sided alpha level of 0.05 for statistical testing was 
used. 
 
3. Results 
Main results are summarized in Table 3.  
 
3.1 Pain score 
No signs of pain were observed for any horse at any time point during the study. 
The highest score recorded on the composite pain scale was 3/36. 
 
3.2 Lameness and symmetry index  
Subjective and objective lameness examinations showed mild to moderate degrees 
of forelimb lameness in 5 out of 9 horses in the first week following treatment. Horses 3, 
5, 6 and 7 showed lameness on the sham-treated limb while horse 4 was lame on the 
treated limb. However, only two of the horses (horse 4 and 5) needed to be treated with a 
short course of NSAID for lameness and swelling of the carpal and metacarpal region on 
days 4, 5 and 6. After 3 days, the treatment was discontinued as both swelling and 
lameness had resolved. On day 30 all horses were sound.  On day 60, two horses (2 and 5) 
showed mild lameness, both on the sham-treated limb. A thorough orthopedic examination 
and diagnostic perineural blocks localized pain to the hoof in both horses. On day 90 all 9 
horses were sound. Since the conclusion of the experimental phase 3 years ago, horses 
included in the study have been closely observed for 1 to 3 years. None of the horses was 
lame due to a clinical relevant carpal pathology. 
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3.3 Carpal variables 
 
Local swelling of the carpi was noticed in all horses at least during the first week 
after arthroscopy. Five horses showed a similar degree of swelling in both carpi; 2 horses 
(horses 4 and 5) showed more swelling in the treated carpi whilst in a further 2 horses 
(horses 3 and 8) the sham-treated carpi were more swollen. 
Compared to baseline on average all horses had an increase in carpal 
circumference in the first week after treatment in both carpi. Although overall this 
appeared more pronounced in the sham-treated joints, there was no statistically significant 
difference compared to the treated joints and all carpi were within 0.5 cm difference in 
circumference 90 days after treatment.  
Five of the 9 horses showed no significant temperature difference between the 
treated and sham-treated carpi at all times. In horse 1 the treated carpus had a relative 
increase of 3.5°C on day 30. Horse 3 had a higher reading in the sham-treated carpus on 
day 4 (10.25 °C) and day 6 (4.6 °C), as did horse 8 on day 6 (2.8 °C) and horse 6 on day 
90 (1.8 °C). 
In 2 horses (horses 1 and 2) palpation of the carpi was not painful at any time. 
Horses 8 and 9 were scored 1 at a single time point, whereas horses 5 and 6 were scored 1 
repeatedly on both carpi. Horses 3 and 7 were scored 1 or 2 on palpation of the sham-
treated carpus and horse 4 at palpation of the treated carpus at several time points during 
the first 14 days. 
There were no significant differences in MNTs between treated and sham-treated 
limbs except for landmark 3 on day 4: treated joints had statistically significant higher 
MNTs than sham-treated joints (P=0.009) (Fig.1). 
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Six out of 9 horses showed no significant changes in range of motion during the 90 
day period. Two horses showed a temporary, reduced range of motion compared to 
baseline, one in the treated limb (horse 4) and one in the sham-treated limb (horse 3), 
which had returned to baseline by day 90. 
 
Three out of 9 horses showed no ultrasonographic joint changes. Horse 7 had a 
score of 1 in the left middle carpal joint before treatment only. Horses 2, 8 and 9 showed a 
score of 1 on both treated and sham-treated carpi at different time points and horses 4, 5 
and 6 had a score of 1 on the sham-treated carpus at different time points. No horse had 
ultrasonographic changes on day 90.  
 
3.4 Needle arthroscopy 
In 4 joints of the 18 joints examined on day 0 clear images could not be captured 
due to hemorrhage. On day 0 a small full thickness lesion was noted on the weight bearing 
surface of the fourth carpal bone in horse 8 and of the second carpal bone in horse 9. Both 
defects were unchanged at the second arthroscopy (day 90).  Time to perform the 
procedure ranged between 30 and 90 minutes (average 63.3 minutes) on day 0, and 
between 30 and 55 minutes (average 38.9 minutes) on day 90. At 90 days, gold particles 
could be seen in the region of the lateral palmar intercarpal ligament of the left middle 
carpal joint in horse 9.  
  
3.5 Blood and synovial fluid analysis 
 
Compared to baseline, hematology, serum chemistry and SAA values showed no 
significant difference throughout the study. No values were outside the normal range at 
any time point.  
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Cell count in all synovial fluid samples was below 100 cells/µl at all time points, therefore 
differentiation was not performed as inflammatory effusion was not suspected. For CS846 
and Substance P all values were within the normal range, while for IL-1β and TNF-α all 
values were below or within the normal range. No differences between treated and sham-
treated joints were found. 
 
4. Discussion 
The current study aimed to evaluate the safety of intra-articular gold micro-
implants mixed with HA in horses. Nine healthy experimental horses without any signs of 
pathology in the carpal region had their middle carpal joint  unilaterally treated with BMI 
mixed with HA while the contralateral side was sham-treated with HA alone. 
 
Our findings indicate that no major clinically relevant differences between the 
treated and the sham-treated joints were detected during the whole study period for any of 
the outcome measures evaluated. 
 
In order to recognize as many potential adverse effects of intra-articular BMI on 
joint homeostasis, a large number of outcome parameters were included. Several 
diagnostic imaging techniques lend themselves for this purpose in vivo. We chose 
ultrasonography for the serial evaluation of the synovial membrane, as this method is easy 
to perform, non-invasive and provided a real time detection of pathological intraarticular 
changes [20].  Furthermore, needle arthroscopy was chosen for real-time macroscopic 
assessment of the target structures as it has been proposed as a minimally invasive 
technique allowing direct visualization without the need for general anesthesia. A thin 
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needle endoscope was used to visualize the middle carpal joints in standing horses as 
previously described [21, 22]. The findings of the present study question just how 
minimally invasive this procedure is, as a relatively high incidence of lameness, swelling 
and increased local sensitivity to palpation and pressure were observed during the first 
week following surgery. Despite the fact that optimal intra-operative sedation and 
analgesia was provided and that the smallest endoscope available was used, adequate 
patient cooperation was vital for surgery to take place without complications. 
Complications (intra-articular hemorrhage, articular and periarticular trauma) resulting in 
the signs observed in the first week following surgery, were more frequent in those horses 
that were least cooperative during the procedure.  For future application, a mechanical 
fixation system might help to keep the correct limb positioning over time, with the carpus 
slightly lifted and flexed. Furthermore, well instructed personnel should be available to 
optimize the procedure while reducing risks of trauma. 
 
The administration of HA in combination with BMI represents a further risk factor 
for side effects of treatment. Occasional adverse reactions to synthetic HA (“joint flare”), 
lasting 3 to 5 days, have been described 1 to 3 days after administration in horses and 
humans [23, 24]. As the viscosity of HA was needed to provide adequate distribution of 
the gold microimplants [10] in the treated joints, HA (and not saline) was also used as the 
control in the sham-treated joints. Hyaluronic acid as a confounding safety factor could 
therefore be largely excluded. 
 
Significant differences between treated and sham treated limbs were found only for 
mechanical nociceptive thresholds as measured by algometry. Higher thresholds were 
found in the treated carpi than in the sham-treated carpi on day 4, on landmark 3, 
corresponding to the dorsal aspect at the mid-body of intermediate carpal bone. Testing of 
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mechanical nociceptive threshold is a method commonly used to assess local sensitivity to 
mechanical stimulation in humans [25]. Using a calibrated spring-loaded instrument it is 
possible to quantify the pressure necessary to evoke pain when applied to a predefined 
anatomical landmark. Higher thresholds correspond to lower pain responses. In an 
experimental model of carpal osteoarthritis, mechanical nociceptive threshold testing of 
the carpal region has been previously validated in horses and shown to be useful in 
differentiating between affected and non –affected limbs as well as to quantify 
postoperative nociceptive sensitization [17]. In the present study, lower baseline threshold 
values in the carpal area were found compared to the previously published reference 
values; this discrepancy can likely be explained by the decreased rate of pressure increase 
applied (approximately one fifth of the previously adopted rate in the current study). This 
rate was chosen as the operator (NM) was able to provide more reliable results. Similar 
rates have previously been described in human studies [25, 26]. 
 
In addition to the higher MNTs found in the treated carpi, other local variables, 
such as temperature, swelling, reaction to palpation and carpal circumference showed a 
similar clinical trend, with lesser  adverse reactions being detected in the treated limbs. 
This may be interpreted as early postoperative analgesic and/or anti-inflammatory effect 
of gold in the treated joints. Further clinical studies are necessary to confirm this clinical 
impression. 
 
Besides the clinical outcome measures, a panel of synovial molecular biomarkers, 
each reflecting specific intra-articular processes, was selected to assess articular health in 
the present study. The pro-inflammatory cytokines TNF-alpha and IL-1β together with 
Substance P, a neuropeptide known to accompany articular pain and inflammation, would 
be expected to increase in the face of  BMI induced  articular inflammation [20, 27]. In 
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case of direct or indirect damage from BMI to cartilage matrix homeostasis, the epitope 
846 of chondroitin should also increase, reflecting enhanced aggrecan turn-over [28, 29]. 
No increases were noted in this study. Arthrocentesis was first performed 7 days after 
treatment in order to avoid further mechanical insults to the operated joint and possible 
partial removal of gold particles. The results of routine joint fluid analyses at 4 time points 
throughout the study showed no clinically or statistically significant differences between 
the treated and the sham-treated carpi and no deviations from baseline values. The 
absence of increase in cell counts and of catabolic, pain and inflammatory biomarkers 
observed in this study indicates that BMI did not adversely affect synovial fluid 
homeostasis in healthy equine joints. 
 
Although gold particles were seen arthroscopically in 1 horse at 90 days the 
distribution of potentially toxic particles was not further evaluated. Previous studies [30] 
investigating the permeability of synovium in healthy and diseased human knees showed 
that synovial micro-vessels are permeable to a molecule radius of up to 1.75-40 nm. While 
gold particles 1-2 nm in size have been shown to be cytotoxic [31], no toxic effects on  
vital organs could be demonstrated after intra-articular injection of 13 and 50 nm gold 
particles in an arthritis model in rats [32]. In the latter study, joint swelling and 
histological changes of the joint decreased significantly when treated with repeated nano-
gold injections. As nano-gold particles are promptly phagocytized by macrophages 
repeated administration is necessary to obtain a persistent anti-inflammatory effect [8]. In 
contrast, one single injection of micro-gold particles (as in the case of BMI) is expected to 
allow permanent release of gold ions, thus establishing longer-lasting local therapeutic 
levels [8, 10, 33].  
The gold particles used in the present study had a diameter of 20-40 µm and were injected 
into healthy joints. Migration outside of the joint and a systemic effect are therefore 
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unlikely. Furthermore, the low concentration of gold ions potentially leaving the joint [8] 
is not expected to cause systemic toxic effects. No changes in SAA concentrations, a 
reliable and very sensitive marker of systemic inflammation and infection [34, 35] were 
seen over the study period. As the first blood sample for SAA determination was collected 
7 days following treatment, we might have missed acute changes of this parameter.    
 
General signs of pain were monitored by use of a multidimensional pain score, 
previously validated in an equine model of experimentally induced arthritis [11] and 
slightly modified for the purposes of the present study. The highest score attributed to any 
horse at any time point was 3/36, indicating minimal or no systemic pain signs throughout 
the study attributable to systemic adverse reactions of BMI. These findings support the 
absence of both systemic and extensive local inflammatory effects after BMI injection.  
 
The present study was limited to a follow up period of 90 days. This duration was 
considered sufficient for adverse reactions to BMI treatment to become manifest. 
Furthermore, all horses included in the study have been under continuous supervision 
since the end of the study. They have been regularly reevaluated for a minimum of 1 year 
up to 3 years and none of the horses ever showed lameness due to a carpal pathology. Ex-
vivo histological articular tissues examination would have provided stronger evidence of 
safety, but would have needed a terminal study design. A further limitation of the present 
study is the low number of subjects included. Indeed, in order to conclusively demonstrate 
absence of adverse effects in studies on medications or implants for human use, 
considerably higher subject numbers are required.  
While a higher number of horses would have been helpful to draw more reliable 
conclusions, the robust study design and the fact that each horse acted as its own control 
make it unlikely that a higher number of horses would have altered the results.  
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5. Conclusion 
Over the primary study period of 90 days we were unable to determine systemic or 
local detrimental effects of a single administration of gold micro-implants injected with 
HA into the middle carpal joint of healthy horses. Given the absence of acute adverse 
findings during the primary study period as well as during the long-term clinical follow-
up of 1-3 years, the results of the present study indicate that the treatment is safe and thus 
support the performance of clinical trials testing efficacy in established sub-acute or 
chronic inflammatory processes. 
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Figures Legend 
Figure 1: Box and whiskers plots representing the medians (midline), 75% and 25% 
percentiles (upper and lower quartiles, respectively) and ranges (upper and lower 
whiskers)of mechanical nociceptive thresholds (MNTs) measured on the dorsal aspect of 
the mid-body of the intermediate carpal bone (landmark 3) of treated joints (dark grey) 
and sham-treated joints (white). * Significant difference between treated and sham-treated 
joints were detected 4 days after treatment administration. 
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Table 1: Demographic data and random treatment assignment 
  
Horse Breed Age (years) Gender Body weight (kg) Treatment 
1 
 Hannoverian 19 gelding 600 sham-treated treated 
2 
 Trotter 10 mare 498 sham-treated treated 
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3 
 
Franche 
Montagnes 10 mare 617 treated sham-treated 
4 
 
Franche 
Montagnes 11 mare 615 treated sham-treated 
5 
 Trotter 10 mare 547 treated sham-treated 
6 
 
Swiss 
Warmblood 13 mare 615 sham-treated treated 
7 
 
Swiss 
Warmblood 11 mare 583 treated sham-treated 
8 
 
Swiss 
Warmblood 14 mare 618 sham-treated treated 
9 
 
Swiss 
Mountain 
Horse 
10 mare 604 treated sham-treated 
 
Breed, age, gender and body weight of the horses included in the study and their 
treatment. Treated: Berlock® Micro-Implants mixed with hyaluronic acid; Sham-treated: 
hyaluronic acid alone 
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Table 2: Outcome parameters assessment schedule 
Study Phase Study Day Week CPS LLP BS SFS US RX NA T 
Pretreatment -14 to -7 -1/-2 x x  x     x     
Treatment 0 0      x x   x x 
Follow-up 
1 
1 
x               
2 x x             
3 x               
4 x x             
5 x               
6 x x             
7 x   x x x       
14 2 x x             
30 4 x x x x x       
60 8 x x             
End of Study 90 12 x x x x x x x   
           
 CPS: Composite Pain Score; LLP: Lameness and local pain assessment, see Appendix 2; 
BS: Blood sampling; SFS: Synovial Fluid sampling; US: Ultrasound examination; RX: 
Radiography; NA: Needle Arthroscopy; T: intra-articular treatment (Berlock® Micro-
Implants mixed with hyaluronic acid) or sham-treatment (hyaluronic acid alone) 
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Table 3: Main results 1 
  
Baseline Week 1 Day 14 Day 30 Day 60 Day 90 
MNT 2 treated  (kg/cm2) 10.9 (7,12) 9.5 (4.9, 11.3) 10.3 (6,12) 10.6 (7.8,12) 10.6 (6.2,12) 11.7 (6.7,12) 
MNT 2 sham (kg/cm2) 10.5 (6.9,12) 9.1 (5.2,11.5) 10.3 (7.2,12) 10.6 (8.9,12) 
11 
(8.9,12) 11.1 (6.9,12) 
MNT 3 treated (kg/cm2) 12 (5.9, 12)  9.4 (4.7,10.4) 12 (5.9,12) 11.3 (7.9,12) 11.8 (7.8,12) 10.3 (6.3,12) 
MNT 3 sham (kg/cm2) 12 (8.5, 12)  8.5 (4.9,12) 10.2 (6.2,12) 10.9 (8.6,12) 
12 
(9.4,12) 10.6 (7.7,12) 
MNT 5 treated (kg/cm2) 11 (7,12) 9.5 (5.6,12) 9.2 (6,12) 10.3 (5.8,12) 10.6 (7.6,12) 10.7 (5.7,12) 
MNT 5 sham (kg/cm2) 10.5 (5.3, 12)  8.7 (5,11.6) 9.7 (6.7,12) 10.4 (8,12) 11.1 (9.1,12) 10 (6.8,12) 
Carpal flexion treated (°) 26 (16,35) 23 (17,40) 22 (14,39) 22 (15,43) 21 (16,37) 20 (17-23) 
Carpal flexion sham (°) 26 (16,34) 21 (15,30) 22 (13,33) 22 (14,30) 21 (17,27) 20 (14,25) 
Circumference treated (cm) 31 (29,34) 32 (30,35) 32 (30,34) 31 (29,34) 32 (29,34) 31 (30,34) 
Circumference sham (cm) 31 (30,33) 32 (30,34) 32 (30,34) 31 (29,33) 31 (30,34) 32 (30,34) 
Symmetry Index (score) 1.01 (0.9,1.22) 1 (0.7,1.75) 1.09 (0.65,1.65) 
0.87 
(0.75,1.27) 
1.1 (0.52-
1.37) 1 (0.87,1.18) 
Aggrecan treated (ng/mL) 9716 (5476, 
20629) 
8220 
(5226,21569)   
6229 
(3416,13156)   
8439 
(3149,30277) 
Aggrecan sham  (ng/mL) 6276 (5340, 
24079) 
8734 
(4816,50844)   
10775 
(5798,37405)   
8400 
(3252,15263) 
IL-1 beta treated (ng/mL) 0.126 (0.09, 
0.168) 
0.128 
(0.079,0.192)   
0.105 
(0.066,0.161)   
0.109 
(0.066,0.154) 
IL-1 beta sham (ng/mL) 0.128 
(0.061,0.186) 
0.105 
(0.09,0.211)   
0.132 
(0.107,0196)   
0.087 
(0.063,0.198) 
TNF-alpha treated (ng/mL) 0 (0, 0.091) 0 (0,0.298)   0 (0,0.271)   0 (0,0.23) 
TNF-alpha sham (ng/mL) 0 (0,0.069) 0 (0,0.301)   0 (0,0.338)   0 (0,02) 
Substance P treated (pg/mL) 7 (6,9) 8 (5,18)   8 (5,14)   7 (4,16) 
Substance P sham (pg/mL) 8 (5,13) 8 (5,18)   7 (6,12)   6 (5,18) 
 2 
Median values and ranges for the main outcome parameters at baseline, week 1, day 14, 3 
30, 60 and 90 after treatment (Berlock® Micro-Implants mixed with hyaluronic 4 
acid)/sham treatment (hyaluronic acid alone). Mechanical Nociceptive Thresholds 5 
(NMTs) are reported for landmark 2, 3 and 5. No significant differences (P<0.05) were 6 
found at any of the reported time point between treated and sham treated joints. 7 
 8 
 9 
